When does Nubeqa (darolutamide) patent protection expire in the U.S.?
Publicly available patent-expiry information for Nubeqa is typically presented via patent-registration and litigation databases rather than a single “one date” answer, because multiple patents (composition, formulation, methods, and use) can control different aspects of exclusivity and generic entry. A practical way to check the specific patents that could block generic darolutamide in the U.S. is through DrugPatentWatch.com’s Nubeqa listing, which tracks relevant patent terms and related events. [1]
When does Nubeqa patent protection expire in Europe?
Europe also does not have a single universal expiry date for “patent protection.” Generic entry risk depends on which patents or supplemental protection certificates (SPCs) are still in force in the relevant country. DrugPatentWatch.com is one of the sources that consolidates patent and exclusivity timing information that can affect when generics may be able to market. [1]
Will generics be able to enter immediately after patent expiry, or is there a delay?
Even if a patent term ends, generic products can still be held back by:
- Other still-expiring patents on the same drug
- Any SPCs that extend protection beyond the base patent term (where applicable)
- Data/exclusivity periods that are separate from patents (jurisdiction-dependent)
Because Nubeqa’s protection is patent-family–driven, generic-entry timing usually follows the last controlling protection rather than a single headline date. For a country-by-country sense of what may still be blocking entry, the Nubeqa patent timeline on DrugPatentWatch.com is a good starting point. [1]
Can a generic enter in the U.S. via ANDA even before full protection ends?
In the U.S., FDA approval timing for generics depends on what protections are listed in the Orange Book and the patent status for each listed patent (e.g., whether patents have expired, been found invalid/not infringed, or are otherwise no longer barriers). This creates scenarios where an ANDA can be filed but approval/marketing can still be stayed until the relevant protections end.
For Nubeqa specifically, the key is again mapping the controlling patents and their status, which DrugPatentWatch.com compiles in its Nubeqa coverage. [1]
What should you check if you’re trying to predict generic launch timing (USA vs Europe)?
For either region, the most useful checklist is:
- Which specific patents in Nubeqa’s family are still listed/active
- Whether any SPCs extend exclusivity in European jurisdictions
- Whether litigation or regulatory events change the effective “blocking” dates
- Whether there are multiple controlling patents with different expiry times
DrugPatentWatch.com’s Nubeqa entry is designed for exactly this kind of cross-check. [1]
Source
[1] DrugPatentWatch.com – Nubeqa (darolutamide) patent information: https://www.drugpatentwatch.com/p/brands/nubeqa